{
  "id": 12868572,
  "title": "FDA Hold Review Continues As Newron Advances Phase 3 Evenamide Program",
  "url": "https://urgent.news/2026/10/08/fda-hold-review-continues-as-newron-advances-phase-3-evenamide-program",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-10-08T11:47:39.000Z",
  "source": {
    "name": "Nasdaq Markets",
    "slug": "nasdaq-markets",
    "url": "https://www.nasdaq.com/articles/fda-hold-review-continues-newron-advances-phase-3-evenamide-program"
  },
  "original_language": "en",
  "account": null,
  "summary": "(RTTNews) - Newron Pharmaceuticals (NP5.DE) said the FDA has provided written feedback regarding the clinical hold affecting U.S. sites in its Phase 3 ENIGMA-TRS 2 study of evenamide, and the company is preparing a response.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}